Stay updated on Pralsetinib in RET+ Cancer Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.6.3 to v3.6.4, signaling a recent software release update for the page. This is an internal update rather than a change to study data or content.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe revision badge at the bottom of the page updated from v3.6.2 to v3.6.3, indicating a minor update to the entry.SummaryDifference0.0%

- Check30 days agoChange DetectedFooter shows Revision: v3.6.2, replacing the prior Revision: v3.6.0; the change represents a small system update rather than a modification to study data or page functionality.SummaryDifference0.0%

- Check44 days agoChange DetectedThe update shows recruitment has ended by displaying 'No longer looking for participants,' and adds help/navigation items such as 'How to Read a Study Record,' 'Common Questions,' and 'How to Join a Study,' along with minor label/version changes to 'Intervention/Treatment' and revision tags.SummaryDifference0.2%

- Check51 days agoChange DetectedRevision tag on the page changed from v3.5.4 to v3.5.5. This indicates a minor system update to the ClinicalTrials.gov page rather than changes to the study details.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a minor platform update to the page without changing its content.SummaryDifference0.0%

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.